These benefits, together with a preceding report demonstrating that a small-molecule ACKR3 agonist CCX771 reveals anxiolytic-like conduct in mice,2 support the notion of targeting ACKR3 as a singular approach to modulate the opioid procedure, which could open up new therapeutic avenues for opioid-associated Issues.Disclaimer: The above mentioned is